AG
BPMC

Artal Group’s Blueprint Medicines BPMC Stock Holding History

Artal Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200,000
Closed -$11.7M – 137
2020
Q1 		$11.7M Buy
200,000
+100,000
+100% +$6.44M 0.49% 41
2019
Q4 		$8.01M Buy
+100,000
New +$7.49M 0.31% 55
2018
Q3 		– Sell
-200,000
Closed -$12.7M – 108
2018
Q2 		$12.7M Buy
200,000
+150,000
+300% +$11.9M 0.27% 39
2018
Q1 		$4.58M Buy
+50,000
New +$4.31M 0.06% 74

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artal Group's BPMC Position: Q4 2021 in Review

Artal Group sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 100,000 shares — an estimated $10.3M sold.

Artal Group first reported a position in BPMC in Q4 2017 and held it in 13 quarters. The position peaked at $70.7M in Q2 2019. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

  • Artal Group reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
  • Artal Group sold 100,000 Blueprint Medicines shares in Q4 2021, an estimated $10.3M.
  • Artal Group first reported a position in Blueprint Medicines in Q4 2017 and held it in 13 quarters.
  • Artal Group's Blueprint Medicines position peaked at $70.7M in Q2 2019.
  • 280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.